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Abstract. Background: Urine uromodu-
lin (uUMOD) is a protein secreted by the 
kidney tubule. Recent studies have suggested 
that higher uUMOD may be associated with 
improved kidney and mortality outcomes. 
Methods: Using a case-cohort design, we 
evaluated the association between baseline 
uUMOD levels and ≥ 30% estimated glo-
merular filtration rate (eGFR) decline, inci-
dent chronic kidney disease (CKD), rapid 
kidney function decline, and mortality using 
standard and modified Cox proportional haz-
ards regression. Results: The median value 
of uUMOD was 25.8 µg/mL, mean age of 
participants was 74 years, 48% were women, 
and 39% were black. Persons with higher 
uUMOD had lower prevalence of diabe-
tes and coronary artery disease (CAD), and 
had lower systolic blood pressure. Persons 
with higher uUMOD also had higher eGFR, 
lower urinary albumin to creatinine ratio 
(ACR), and lower C-reactive protein (CRP). 
There was no association of uUMOD with 
> 30% eGFR decline. In comparison to those 
in the lowest quartile of uUMOD, those in 
the highest quartile had a significantly (53%) 
lower risk of incident CKD (CI 73%, 18%) 
and a 51% lower risk of rapid kidney func-
tion decline (CI 76%, 1%) after multivariable 
adjustment. Higher uUMOD was associated 
with lower risk of mortality in demographic 
adjusted models, but not after multivari-
able adjustment. Conclusion: Higher levels 
of uUMOD are associated with lower risk 
of incident CKD and rapid kidney function 
decline. Additional studies are needed in the 
general population and in persons with ad-
vanced CKD to confirm these findings.
Introduction
The current assessment of kidney health 
and the definition of chronic kidney disease 
(CKD) are limited to measures or estimates 
of glomerular filtration rate (eGFR) and uri-
nary albumin-creatinine ratio (ACR). Tu-
bular health is essential for maintenance of 
acid-base status, mineral metabolism, and 
hormone production [1, 2]. In addition, tu-
bular secretion is also the means by which 
medications are excreted through the kid-
neys. The kidney tubules may also have a 
role in preventing urinary infections. How-
ever, there are no biomarkers that have be-
come accepted in clinical medicine as vali-
dated measures of tubular health.
Urinary uromodulin (uUMOD), also 
known as Tamm-Horsfall protein, is a 
 95-kDa glycoprotein synthesized by the 
thick ascending limb of the loop of Henle 
and early distal convoluted tubule. It is 
the most abundant urinary protein among 
healthy adults (20 – 70 mg/day) [3]. Muta-
tions in the UMOD gene are associated with 
low uUMOD levels and cause congenital 
hyperuricemic, cystic kidney diseases, and 
kidney failure [4, 5]. In large genome-wide 
association studies (GWAS), the strongest 
associations with CKD were with common 
variants in the region of UMOD gene [6, 7]. 
As a result, there has been a renewed interest 
in the role of uUMOD in the development 
and progression of kidney disease.
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Recently, our group has found that among 
participants enrolled in Cardiovascular Health 
Study (CHS), each standard deviation (SD) 
higher uUMOD was associated with 23% 
lower odds of eGFR decline in models adjust-
ed for demographics, eGFR, ACR, and CKD 
risk factors [8]. In addition, each SD higher 
uUMOD was also associated with 10% lower 
risk of mortality in adjusted models.
In the Health, Aging & Body Composi-
tion study (Health ABC), we aimed to vali-
date our previous work and evaluate the 
association between uUMOD levels, kid-
ney function decline, and mortality in older 
adults. We hypothesize that lower uUMOD 
concentrations may serve as a noninvasive 
method of assessing impaired tubular health 
and identifying persons at higher risk for 
progressive kidney disease and mortality.
Methods
Participants
The Health ABC is a longitudinal study 
of the impact of changes in weight and body 
composition on age-related physiologic and 
functional changes. Community-dwelling 
adults (n = 3,075) aged 70 – 79 years were 
recruited from Medicare eligibility lists from 
March 1997 through July 1998 at two field 
centers in Pittsburgh, PA, and Memphis, TN. 
White participants were recruited from a ran-
dom sample of the lists; black participants 
were recruited from all age-eligible individ-
uals residing in the respective communities. 
Subjects were eligible if they reported no dif-
ficulty walking one-fourth of a mile, climb-
ing up 10 steps, or performing basic activities 
of daily living; were free of life-threatening 
illness; planned to remain in the geographic 
area for ≥ 3 years; and were not enrolled in 
lifestyle intervention trials. Exclusion crite-
ria included difficulties with activities of dai-
ly living, cognitive impairment, inability to 
communicate with the interviewer, intention 
of moving within the next 3 years, and active 
treatment for cancer in the preceding 3 years. 
All participants gave informed consent, and 
the study was approved by the institutional 
review boards at the University of Tennessee 
Health Science Center and the University of 
Pittsburgh.
Study design
We used a case-cohort design for this 
study, and Figure 1 depicts the sampling 
design for this study strategy. From the en-
tire cohort of Health ABC (n = 3,075), we 
selected a random subcohort of 502 partici-
pants at year 1. Our primary outcomes were 
≥ 30% eGFR decline and mortality. In ad-
dition to the random subcohort, cases were 
selected for ≥ 30% eGFR decline to ensure 
sufficient number of events and adequate sta-
tistical power. We defined decline as ≥ 30% 
decline in eGFR from the year-1 visit to the 
year-10 visit. If year 10 was missing, we 
used eGFR from the year-3 visit. Overall, 
there were 420 participants who had ≥ 30% 
decline in eGFR during the study period. Of 
these, 81 were already in the random subco-
hort, and an additional 339 participants with 
> 30% eGFR decline were identified from 
the entire Health ABC study population. As 
secondary outcomes, we also assessed for 
incident CKD (eGFR < 60 mL/min/1.73m2 
and at least 1 mL/min/1.73m2/year decline 
in eGFR in individuals with eGFR ≥ 60 mL/
Figure 1. Selection of study participants. Sampling 
strategy for the present study. Of 3,075 participants 
at year 1, a representative random subcohort of 502 
participants was created. All cases of ≥ 30% eGFR 
decline from outside the subcohort were sampled 
to maximize statistical power. Cases of mortality 
and the secondary kidney outcomes of rapid kidney 
function decline and incident CKD were from within 
the subcohort. KF = kidney function.
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min/1.73m2 at baseline) and rapid kidney 
function decline (> 3 mL/min/year decline in 
eGFR) in the subcohort only. As there were 
sufficient mortality events (n = 248) from 
within the random subcohort, we did not ad-
ditionally sample for mortality. In aggregate, 
the random subcohort and the CKD progres-
sion cases provided an analysis cohort of 841 
participants.
Exposure variable
Spot urine specimens were obtained at 
the time of the year-1 study visit and stored 
at –70 °C until thaw and uUMOD was mea-
sured at the University of Cincinnati Chil-
dren’s Hospital Medical Center in 2015. 
Uromodulin was assayed in the urine using 
a commercially-available ELISA kit (MD 
Bioproducts, St. Paul, MN, USA) accord-
ing to the manufacturer’s instructions. The 
assay is based on a colorimetric sandwich 
immunoassay utilizing a polyclonal antibody 
against human uromodulin as the capture 
antibody and a biotinylated polyclonal anti-
body against human uromodulin as the de-
tection antibody. The correlation coefficient 
for this particular assay run was 1.00. The in-
terassay coefficient of variation obtained by 
analyzing results from 81 duplicate measures 
spread between 10 separate assay runs was 
as 5.02%. The minimum detectable concen-
tration as reported by the manufacturer was 
0.75 ng/mL. No measured values in our co-
hort were below the detectable limit.
Outcomes
The eGFR was estimated using an equa-
tion that included serum cystatin C concen-
tration, age, sex, and race derived in the 
CKD-EPI study [9]. A 30% decline in eGFR 
has recently been associated with adverse 
outcomes and therefore recommended as an 
alternative endpoint for CKD progression 
[10]. In secondary analysis, we used incident 
CKD (eGFR < 60 at year 3 or 10 and at least 
1 mL/min decline in eGFR) and rapid kidney 
function decline defined by > 3 mL/min/year 
decline in eGFR, given their association with 
adverse clinical outcomes in prior studies 
[11]. Cystatin C was measured using a BNII 
nephelometer (Dade Behring Inc., Deerfield, 
IL, USA) that used a particle-enhanced im-
munonephelometric assay (N Latex Cystatin 
C) [12]. We used cystatin C-based eGFR es-
timates as creatinine was not isotope dilution 
mass spectrometry (IDMS) standardized at 
all the visits during follow-up thus increas-
ing the risk of bias due to measurement vari-
ability.
The Health ABC Study Diagnosis and 
Disease Ascertainment Committee reviewed 
all hospital records, death certificates, infor-
mant interviews, and autopsy data to adju-
dicate immediate and underlying causes of 
death.
Covariates
Covariates for the models were selected 
a priori based on biological plausibility and 
prior published data regarding potential con-
founders of the associations of uUMOD with 
the clinical endpoints [8]. A series of sequen-
tial models were fit to evaluate the effects of 
adding certain sets of covariates. Traditional 
cardio-vascular disease (CVD) and kidney 
disease risk factors including age, gender, 
race/ethnicity, body mass index (BMI), phys-
ical activity level, smoking defined by current 
versus former (> 100 lifetime cigarettes) or 
never, diabetes (defined by use of hypoglyce-
mic agents, fasting plasma glucose > 126 mg/
dL or nonfasting glucose ≥ 200 mg/dL), sys-
tolic blood pressure, low-density lipoprotein 
cholesterol level (LDL), high-density lipo-
protein cholesterol level (HDL), statin medi-
cations, blood pressure medications including 
angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, calcium chan-
nel blockers, diuretics, and C-reactive protein 
(CRP) were considered as confounding vari-
ables. Analyses were also adjusted for base-
line eGFR and ACR.
Statistical analysis
We described the distribution of uUMOD 
using summary statistics and frequency his-
tograms and compared baseline participant 
characteristics (demographics, kidney func-
tion, CVD risk factors) by uUMOD quartiles 
among members of the subcohort. We evalu-
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ated the correlations of uUMOD, eGFR, and 
albuminuria using Spearman correlation co-
efficients. We evaluated each uUMOD-out-
come association for the presence of nonlin-
earity using generalized additive models and 
restricted cubic splines. Risk estimates were 
calculated by categories of uUMOD (defined 
by quartiles of the distribution among the 
random subcohort) for all outcomes.
We evaluated the association of uUMOD 
with eGFR decline, using modified Cox re-
gression to account for the case-cohort ap-
proach [13, 14]. Subcohort participants were 
weighted with the inverse of the sampling 
fraction. Cases that arose outside the subco-
hort were not weighted before their failure. 
All cases (irrespective of whether they arose 
in the subcohort or not) were assigned a 
weight of 1 at the time of failure. For each 
outcome, we fit a series of sequential mod-
els. Initial models were adjusted for age, sex, 
race, and clinic site. A subsequent model ad-
ditionally adjusted for baseline eGFR and 
urine ACR. A final model included CVD and 
CKD risk factors (body mass index, diabe-
tes, systolic blood pressure, blood pressure 
medication use, total cholesterol, lipid-low-
ering medication, CRP, and smoking status). 
We evaluated associations of uUMOD with 
mortality using a standard Cox proportional 
hazards regression. For the secondary analy-
sis of kidney outcomes (incident CKD and 
rapid kidney function decline), we used stan-
dard Cox proportional hazards regression as 
these cases were restricted to the random sub-
cohort, and no additional sampling was per-
formed. The proportional hazards assumption 
was tested based on an extended version of 
the Schoenfeld residuals weighted Cox mod-
els [15]. For each of the clinical outcomes, 
Table 1. Baseline characteristics of older community-living adults by quartiles of urine uromodulin (uUMOD).
uUMOD, µg/mL
Quartile 1 Quartile 2 Quartile 3 Quartile 4 All
≤ 15.80 15.81 – 25.86 25.87 – 40.27 > 40.27
N 126 125 126 125 502
Age 74 ± 3 74 ± 3 74 ± 3 73 ± 3 74 ± 3
Female 48 54 47 46 48
Black 41 39 33 43 39
Site
 Memphis 54 58 48 48 52
 Pittsburgh 46 42 52 52 48
Education
 < High school 26 24 20 22 23
 High school 41 31 38 26 34
 Postsecondary 33 45 42 52 43
Diabetes 33 21 23 20 24
Hypertension 70 65 60 63 65
SBP 138 ± 22 134 ± 22 132 ± 19 133 ± 20 134 ± 21
Smoking
 Never 41 42 40 38 40
 Former 48 53 52 54 52
 Current 10 5 8 8 8
BMI, kg/m2 27 ± 4 27 ± 4 27 ± 5 27 ± 4 27 ± 4
CRP*, mg/L 1.81 [1.07, 3.70] 1.50 [0.95, 3.27] 1.47 [1.00, 2.72] 1.64 [0.91, 2.70] 1.63 [0.98, 2.95]
LDL cholesterol, mg/dL 118 ± 35 118 ± 35 122 ± 34 123 ± 36 121 ± 35
HDL cholesterol, mg/dL 52 ± 17 56 ± 18 52 ± 17 52 ± 16 53 ± 17
eGFR, mL/min/1.73m2 70 ± 21 74 ± 18 74 ± 17 74 ± 17 73 ± 18
ACR*, mg/g 12 [5, 37] 8 [5, 17] 6 [4, 15] 8 [4, 17] 5 [4, 20]
Calcium (n = 474) 8.8 ± 0.4 8.8 ±0.4 8.8 ± 0.4 8.8 ± 0.4 8.8 ± 0.4
Phosphorus (n = 470) 3.6 ± 0.5 3.6 ± 0.4 3.5 ± 0.5 3.5 ± 0.5 3.5 ± 0.5
PTH (n = 475) 34 [26, 47] 31 [23, 44] 31 [24, 41] 34 [25, 43] 32 [25, 44]
SBP = systolic blood pressure; BMI = body mass index; CRP = C-reactive protein; LDL = low-density lipoprotein, HDL = high-density 
lipoprotein; eGFR = estimated glomerular filtration rate; ACR = albumin to creatinine ratio; PTH = parathyroid hormone. All values 
represented as % or mean ± SD except those marked with * indicating median [interquartile range].
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we evaluated whether the uUMOD-outcome 
association was modified by CKD status (de-
fined as eGFR < 60 mL/min/1.73m2).
Analyses were conducted using R version 
3.2.2 (2015-08-14) (R Core Team, Vienna, 
Austria) and IBM SPSS Statistics for Win-
dows, Version 23.0. (IBM Corp, Armonk, 
NY, USA) [16]. Estimates with two-sided 
p-values < 0.05 were considered statistically 
significant.
Results
Baseline characteristics
Among the 502 randomly-selected par-
ticipants at baseline, the median (Q1, Q3) 
value of uUMOD was 25.8 µg/mL (15.8, 
40.2), and the distribution was right skewed. 
The mean ± SD age of participants was 
74 ± 3 years, 48% were women, and 39% 
were black. The mean ± SD eGFR was 
73 ± 18 mL/min/1.73 m2, and median (Q1, 
Q3) urine ACR was 5 (4, 20) mg/g. Table 1 
shows baseline characteristics by quartiles 
of  uUMOD in the random subcohort. Com-
pared to participants with low uUMOD, per-
sons with higher levels were less likely to 
have diabetes or history of coronary artery 
disease (CAD), and had lower systolic blood 
presuure (BP). Persons with higher uUMOD 
also had higher eGFR, lower urinary ACR, 
and lower CRP. At baseline, uUMOD levels 
were weakly and inversely correlated with 
ACR (Spearman r = –0.11).
Table 2. Association of uUMOD with kidney outcomes and mortality in older community-living adults.
 uUMOD quartiles Linear model
1 2 3 4 Per SD increase = 
27.1 µg/mL
p-value
≤ 15.80 15.81 – 25.86 25.87 – 40.27 > 40.27
≥ 30 eGFR decline (case-cohort design)
N 126 125 126 124 501
Events 26 10 23 22 81
Incidence rate (%/yr)* 3.22 1.2 2.38 2.49 2.32
Model 1** 1.00 (ref) 0.74 (0.48, 1.13) 0.64 (0.41, 0.99) 0.90 (0.58, 1.40) 1.02 (0.86, 1.20) 0.864
Model 2† 1.00 (ref) 0.80 (0.52, 1.23) 0.78 (0.50, 1.21) 0.94 (0.60, 1.49) 1.03 (0.86, 1.23) 0.792
Model 3‡ 1.00 (ref) 0.82 (0.53, 1.26) 0.93 (0.60, 1.44) 1.10 (0.69, 1.75) 1.08 (0.90, 1.29) 0.418
Incident CKD (subcohort only)
N 126 125 126 124 501
Events 46 31 33 22 132
Incidence rate (%/yr) 5.70 3.72 3.41 2.49 3.78
Model 1** 1.00 (ref) 0.62 (0.39, 0.99) 0.50 (0.31, 0.80) 0.40 (0.23, 0.69) 0.75 (0.58, 0.97) 0.029
Model 2† 1.00 (ref) 0.69 (0.43, 1.11) 0.59 (0.36, 0.97) 0.44 (0.25, 0.76) 0.77 (0.61, 0.99) 0.037
Model 3‡ 1.00 (ref) 0.68 (0.41, 1.11) 0.63 (0.38, 1.05) 0.47 (0.27, 0.82) 0.79 (0.52, 1.01) 0.055
Rapid kidney function decline (subcohort only)
N 88 103 104 94 389
Events 28 15 32 16 91
Incidence rate (%/yr) 4.79 2.17 3.91 2.40 3.3
Model 1** 1.00 (ref) 0.35 (0.17, 0.69) 0.67 (0.39, 1.16) 0.43 (0.22, 0.83) 0.73 (0.52, 1.02) 0.064
Model 2† 1.00 (ref) 0.37 (0.18, 0.75) 0.66 (0.38, 1.16) 0.50 (0.25, 0.98) 0.77 (0.55, 1.07) 0.123
Model 3‡ 1.00 (ref) 0.35 (0.16, 0.73) 0.60 (0.33, 1.10) 0.49 (0.24, 0.99) 0.76 (0.55, 1.06) 0.109
All-cause mortality (subcohort only)
N 126 125 126 125 502
Events 68 68 55 57 248
Incidence rate (%/yr) 5.40 5.23 3.85 4.28 4.66
Model 1** 1.00 (ref) 0.87 (0.61, 1.24) 0.57 (0.39, 0.83) 0.63 (0.43, 0.92) 0.81 (0.68, 0.96) 0.017
Model 2† 1.00 (ref) 0.95 (0.67, 1.36) 0.65 (0.44, 0.94) 0.70 (0.48, 1.02) 0.84 (0.71, 0.99) 0.040
Model 3‡ 1.00 (ref) 1.09 (0.75, 1.59) 0.74 (0.50, 1.10) 0.79 (0.53, 1.17) 0.86 (0.73, 1.02) 0.084
*Incidence rate for > 30 eGFR decline is calculated from the random subcohort only. **Adjusted for age, gender, race, education, and 
site. †Additionally adjusted for estimated glomerular filtration rate and urine albumin-creatinine ratio. ‡Additionally adjusted for diabe-
tes, systolic blood pressure, antihypertensive medications, smoking status, body mass index, low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol, statin use, and C-reactive protein.
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uUMOD and kidney outcomes
There were 420 participants with ≥ 30% 
decline of eGFR during the follow-up period. 
There was no association of uUMOD when 
analyzed as a continuous variable (per SD 
increase) or as quartiles with ≥ 30% eGFR 
decline (Table 2). In secondary analyses re-
stricted to only the random subcohort, there 
were 91 incident CKD events and 132 par-
ticipants who experienced rapid kidney func-
tion decline. Compared to the participants in 
the first quartile, participants in the fourth 
quartile of uUMOD had > 50% lower hazard 
of incident CKD (HR 0.47 (0.27, 0.82)), after 
adjusting for confounders. Similarly, persons 
in the highest quartile of uUMOD also had a 
statistically significant lower hazard of rapid 
kidney function decline compared to persons 
in the lowest quartile of uUMOD (HR 0.49 
(0.24, 0.99)).
uUMOD and mortality
There were 248 deaths within the sub-
cohort over the duration of follow-up. After 
adjusting for age and demographics, each 
1-SD higher uUMOD was associated with 
a 16% lower risk of death. This association 
lost statistical significance after adjusting for 
additional comorbidities and eGFR. After 
multivariable adjustment, the highest quar-
tile of uUMOD was not associated with a 
statistically-significant risk of death in com-
parison with the lowest quartile (HR 0.79, 
(0.53, 1.17)) (Table 2).
We found no evidence of interaction be-
tween eGFR < 60 and uUMOD with the out-
comes of ≥ 30% eGFR decline (p = 0.33), 
incident CKD (p = 0.14) or rapid kidney func-
tion decline (p = 0.80), and mortality (0.98).
Discussion
In summary, for two of our three kidney 
outcomes, and for mortality, we noted that 
higher levels of uUMOD were associated 
with a lower risk, although the results were 
not statistically significant in all models. 
These findings are consistent, in direction 
and magnitude, with prior data in older adults 
wherein we demonstrated that persons in the 
highest quartile of uUMOD had a lower risk 
of ≥ 30% eGFR decline and mortality [8].
The mechanisms linking uUMOD to 
kidney function decline may involve the 
prevention of urinary infections [17], stone 
formation [18] and its anti-inflammatory 
effects after tubular injury [19], although a 
clear causal role has yet to be established. 
As uUMOD is produced by kidney tubule 
cells, it is also possible that higher levels 
of  uUMOD indicate better tubular function, 
such as erythropoietin production, mainte-
nance of acid-base and mineral metabolism 
homeostasis.
Prior studies evaluating the association 
of uUMOD with kidney disease have shown 
conflicting results [6, 8, 20, 21]. These may 
in part be explained by select patient popu-
lations, small sample sizes, severity of un-
derlying kidney disease, and differences in 
uUMOD assays. It has also been hypoth-
esized that during renal injury, uUMOD may 
be upregulated and contribute to the repair 
of the kidney, whereas persistent injury and 
inflammation may result in fixed or lower 
levels of uUMOD [22], thus resulting in a bi-
modal association as has been demonstrated 
previously [23]. It has been postulated that 
polymorphisms in the UMOD gene seen in 
GWAS studies [6, 24] may lead to a pheno-
type with increased uUMOD expression, de-
creased membrane-anchoring efficiency, and 
faster protein trafficking or increased pro-
teolytic release, which is associated with an 
increased risk of adverse clinical events [25].
Recently, two studies evaluated the clini-
cal correlates of uUMOD in large population 
cohorts. The first study included two cohorts; 
the Swiss Kidney Project on Genes in Hyper-
tension study in which 817 participants with 
kidney ultrasound measures provided 24-
hour urine collections, and the Cohorte Lau-
sannoise study cohort in which 5706 adults 
provided morning spot urine samples [26]. In 
the second study, data from 943 participants 
in the CARTaGENE study were analyzed to 
study the determinants of uromodulin excre-
tion in the general population aged 40 – 69 
years [27]. Both studies reported significant 
positive correlation between uUMOD levels 
and eGFR after adjusting for multiple con-
founders. In addition, a positive correlation 
was found between higher uUMOD excre-
tion and urinary sodium, chloride, and uric 
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acid excretion, suggesting a potential role in 
salt and water homeostasis. Further, a posi-
tive linear correlation between uUMOD and 
kidney length and volume led the investiga-
tors to hypothesize that uUMOD may be a 
surrogate for kidney tubular function and 
reserve [26]. Additionally, two more recent 
studies in humans have shown that higher 
uUMOD levels are associated with a signifi-
cantly lower risk of urinary tract infection 
(UTI) in community-dwelling older adults 
[17] and with lower risk of AKI in persons 
undergoing cardiac surgery [28]. Our study 
adds to this growing body of literature sug-
gesting that higher  uUMOD levels may be 
associated with better kidney function and 
clinical outcomes.
Our study is limited by a number of fac-
tors that should be considered. First, par-
ticipants in the Health ABC cohort, although 
elderly, had relatively well-preserved kidney 
function. It is therefore unknown whether 
uUMOD would be differentially associated 
with outcomes in those with proteinuria and 
more advanced kidney disease. Although 
we found no evidence for an interaction 
with CKD, the small sample size limits the 
statistical power. Second, we used a single 
measure of kidney function at follow-up to 
determine eGFR decline, incident CKD, and 
rapid kidney function decline, which should 
ideally have been confirmed by a second 
value. Third, the findings of higher uUMOD 
being associated with less kidney function 
loss was limited to our secondary outcomes 
of incident CKD and rapid kidney function 
decline, and therefore need to be interpreted 
cautiously. Fourth, the samples in our study 
had been stored for nearly 15 years prior to 
analysis. Although storage even at –80 °C 
for 8 months can decrease levels of uUMOD 
[29], we believe this should be nondiffer-
ential with respect to the clinical outcomes. 
Our study also has a number of strengths. 
Figure 2. Unadjusted restricted cubic splines evaluating the association between uUMOD and outcomes. 
Left to right and top to bottom: > 30 glomerular filtration rate (GFR) decline, incident chronic kidney disease 
(CKD), rapid kidney function decline (> 3 mL/min/year), and mortality. Each model was fitted using a re-
stricted cubic spline function for urinary uromodulin (uUMOD). In each plot, the solid line represents the 
curve estimates, and the dotted lines represent 95% confidence bands. The histogram below the cubic 
splines represents the frequency of events per 10 µg/mL uUMOD increments.
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The Health ABC cohort has detailed as-
certainment of risk factors, covariates, and 
outcomes as well as the ability to adjust 
for measures of kidney function. We used a 
laboratory that has extensive experience with 
these measures including using the same as-
say as has been done in prior studies [8, 28].
In summary, results from our study are 
consistent with prior data indicating that 
higher levels of uUMOD may imply “health-
ier tubules” and better prognosis from the 
kidney and mortality standpoint. These find-
ings improve our understanding of the different 
facets of kidney health and function above and 
beyond the traditional measures of eGFR and 
ACR. Studies are needed in more generaliz-
able populations and those with more advanced 
stages of CKD to evaluate whether higher lev-
els of uUMOD are similarly associated with 
better kidney and mortality outcomes.
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